M. Lunnon

发表

Does the Unfavorable Pharmacokinetic and Pharmacodynamic Profile of the iNOS Inhibitor GW273629 Lead to Inefficacy in Acute Migraine?

F. Vanmolkot, B. Laurijssens, J. Palmer, 2009, Journal of clinical pharmacology.

The current status of antihypertensive treatments: into the new millennium

T. Hardman, M. Lunnon, 2001, Expert opinion on pharmacotherapy.

The impact of molecular medicine upon early cardiovascular drug development.

M. Braddock, M. Lunnon, Martin Braddock, 2000, British journal of clinical pharmacology.

Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ET) antagonist, in the human forearm blood flow model.

I. Wilkinson, B. Albala, B. Laurijssens, 2010, British journal of clinical pharmacology.

Pharmacogenetics Working Party: introduction

S. Holgate, M. Lunnon, 2001, International Journal of Pharmaceutical Medicine.

Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions.

K. Lees, K. Muir, J. Posner, 2003, British journal of clinical pharmacology.

Pharmacogenetics Working Party

M. Lunnon, 2000, International Journal of Pharmaceutical Medicine.

Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache

A. Kirkham, L. Harnisch, B. Laurijssens, 2010, Cephalalgia : an international journal of headache.

Use of isradipine in hypertension following coronary artery bypass surgery.

S. Davies, R. Feneck, M. Lunnon, 1989, The American journal of medicine.

Clinical cardiac electrophysiologic evaluation of the positive inotropic agent, DPI 201-106.

A. Camm, G. Butrous, J. Erwin, 1988, European heart journal.

Comparison of isradipine with nitroprusside for control of blood pressure following myocardial revascularization: effects on hemodynamics, cardiac metabolism, and coronary blood flow.

S. Davies, R. Feneck, M. Lunnon, 1991, Journal of cardiothoracic and vascular anesthesia.

Neuroprotection as Initial Therapy in Acute Stroke

J. Ferro, M. Eliasziw, E. Wijdicks, 1998, Cerebrovascular Diseases.

Fungal products. Part 21. Biosynthesis of the fungal metabolite, wortmannin, from [1,2-13C2]-acetate

T. J. Simpson, M. Lunnon, J. Macmillan, 1979 .

Fungal products. Part XVIII. 13C nuclear magnetic resonance spectrum and biosynthesis of colletodiol

M. Lunnon, J. Macmillan, 1976 .

Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis

R. Naoumova, D. Haskard, A. Randi, 2005, Journal of thrombosis and haemostasis : JTH.

Report on the Royal Society of Medicine one day meeting on coronary artery disease - ‘Bench to Bedside’.

M. Lunnon, 2000, Expert opinion on pharmacotherapy.

Making Progress in the Acute Treatment of Stroke

M. James, M. Lunnon, 2005, International Journal of Pharmaceutical Medicine.

Safety and Tolerability of 619C89 after Acute Stroke

K. Lees, K. Muir, S. Hobbiger, 1998, Cerebrovascular Diseases.

A Randomized, Double‐Blind, Placebo‐Controlled Ascending Dose Tolerance Study of 619C89 in Acute Stroke

K. Lees, K. Muir, S. Hobbiger, 1995, Annals of the New York Academy of Sciences.

Effects of the inotrope DPI 201-106 on cardiac performance following cardiac surgery.

R. Feneck, M. E. Davis, M. Lunnon, 1990, International journal of cardiology.

Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions

M. Lunnon, Uta Merle, Thomas Forst, 2023, British journal of clinical pharmacology.